Document is current
Any future updates will be listed below
-
Authors
Pathak, Gita A.
Pietrzak, Robert H.
Lacobelle, AnnMarie
Overstreet, Cassie
Wendt, Frank R.
Deak, Joseph D. https://orcid.org/0000-0002-0540-6080
Friligkou, Eleni https://orcid.org/0009-0003-3682-0991
Nunez, Yaira Z.
Montalvo-Ortiz, Janitza L. https://orcid.org/0000-0002-7657-8365
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 16 September 2024
Revised: 8 April 2025
Accepted: 10 April 2025
First Online: 17 April 2025
Competing interests
: RP received a research grant from Alkermes outside the scope of the present study. RP and JG are paid for their editorial work on the journal Complex Psychiatry. JG and HRK are holders of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics. FRW is an employee of Regeneron Pharmaceuticals with no conflict of interest related to any intellectual property of the company. The other authors have no competing interests to report.
